Table 57Survival outcomes: TACE compared with TEA (TAE) case series studies

Study
Rating
Group
N
InterventionSurvival Time FromMedian OS (95% CI)% Survival Year 1% Survival Year 2% Survival Year 3% Survival Year 4% Survival Year 5
Bargellini et al. 201164
Fair
TACE
67
TACE with lipiodol (mean: 16.1 mL, range: 10–25 mL), epirubicin hydrochloride (mean: 57 mg, range: 40–75 mg), and gelatin sponge particles via hepatic arteryStudy treatmentNot reached90.986.180.5NRNR
Buijs et al. 200865
Fair
TACE
190
TACE with cisplatin (100 mg), doxorubicin (50 mg), mitomycin C (10 mg) in a 1:1 mixture with iodized oil, and either polyvinyl alcohol particles or gelatin-coated trisacryl microspheres via femoral arteryHCC diagnosis16583929NRNR
Giannini et al. 201068
Poor
TACE
128
TACE with an emulsion of Lipiodol and chemotherapeutic agent (doxorubicin, epirubicin, mitoxantrone)HCC diagnosis38*NRNRNRNRNR
Guiu et al. 200969
Fair
TACE
43
TACE with pirarubicin (50 mg) diluted in 5% glucose (20 mL), Lipiodol (20 mL), particles of gelatin sponge (2–3 mm diameter), and amiodarone (150 mg) via femoral artery once every 6-8 weeksHCC diagnosis29 (13.8 to 45)68554727NR
Imai et al. 201170
Poor
TACE
122
TACE with miriplatin (median 80 mg, range 20–120 mg) and lipiodol (median 3 mL, range 1–6 mL) via hepatic arteryNRNRNRNRNRNRNR
Kawaoka et al. 200972
Poor
TACE
107
TACE with lipiodol and cisplatin (total per case median: 60 mg, range 10–390 mg) with or without embolization via femoral arteryStudy treatment25*86NR40NR20
Kim et al. 201283
Poor
TACE
1
TACE for 6 sessions in one case, unknown schedule in the other caseNRNRNRNRNRNRNR
Leelawat et al. 200873
Poor
TACE
15
TACE with mitomycin C (5–10 mg) in a mixture of ionized oil contrast medium and Ivalon particlesStudy treatment15*NR40NRNRNR
Mabed et al. 200975
Fair
TACE
50
TACE using lipiodol (10 mg), doxorubicin (50 mg) and cisplatin (50 mg) via hepatic artery every 4 weeks as long as the condition permits and total dose of 500 mg/m2 not exceededStudy treatment9.5NRNRNRNRNR
Maeda et al. 200876
Fair
TACE
33
TACE with iodized oil, epirubicin (accumulated dose average 16.1 mg, range 0–72.5 mg) and gelatin sponge via hepatic artery for an average of 2.3 sessions (range 1–7 sessions)Study treatmentNot yet reached93.585.277.4NRNR
Molinari et al. 200678
Poor
TACE
47
TACE with doxorubicin (75 mg/m2) with lipiodol (10 mL) followed in some patients with polyvinyl alcohol particles via hepatic artery or superselectively in some casesStudy treatmentNot yet reached76.655.550.0NRNR
Reso et al. 200984
Poor
TACE
1
TACE with cisplatin (50 mg), adriamycin (50 mg) and lipidol (20 mL)NRNRNRNRNRNRNR
Wu et al. 201081
Poor
TACE
110
TACE with epirubicin and lipiodol and/or gelfoam spongeStudy treatment17.7 (14.6 to 19.4)NRNRNRNRNR
Zhang et al. 201182
Good
TACE
277
TACE with 5-fluorouracil (1 g), cis-dichlorodiamine platinum (80 mg), mitomycin (10 mg) mixed with lipiodol (5–30 mL) and, for some patients, gelatin sponge, via hepatic artery repeated every 8–12 weeks until stabilization of the tumorStudy treatment16.752.131.820.2NR11.3
Wu et al. 201081
Poor
TACE with 131 I-metuximab
132
TACE with I-metuximab131 (median 1720 MBq, 95% CI, 1654 to1804 MBq), epirubicin, lipiodol and/or gelfoam sponge via trans-hepatic artery for 5-10 minStudy treatment21.2 (18.6 to 23.4)79.1NRNRNRNR
Leelawat et al. 200873
Poor
TACE-Doxorubicin
15
TACE with doxorubicin (25–50 mg) plus mitomycin C (5–10 mg) in a mixture of ionized oil contrast medium and Ivalon particlesStudy treatment25*NR38NRNRNR
Pietrosi et al. 200949
Poor
TACE or TAE
320
Transarterial chemoembolization with epirubicin (50 mg/m2) with or without iodized oil and/or Gelfoam via hepatic artery or transarterial embolization with iodized oil and/or Gelfoam via superselective artery supplying a single lesion or hepatic arteryStudy treatmentNR73.853.944.7NRNR
Rand et al. 200579
Good
TAE
46
TAE with tirsacryl gelatin microspheres (size 100–700 μ) followed by cyanoacrylate (0.3–1 mL) and lipiodol via hepatic arteriesHCC diagnosis22.270.7NRNRNRNR
*

Extrapolated from Kaplan-Meier graphs.

Abbreviations: CI = confidence interval; HCC = hepatocellular carcinoma; N = number of patients; NR = not reported; NS = nonsignificant; OS = overall survival; TACE = transarterial chemoembolization; TAE = transarterial embolization.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.